Patents Assigned to SAGE THERAPEUTICS
-
Patent number: 12129276Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, Y, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6a, R6b, R7, and R8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: March 2, 2023Date of Patent: October 29, 2024Assignee: SAGE THERAPEUTICS, INC.Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
-
Patent number: 12129275Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.Type: GrantFiled: March 29, 2022Date of Patent: October 29, 2024Assignee: SAGE THERAPEUTICS, INC.Inventors: Ravindra B. Upasani, Boyd L. Harrison, Benny C. Askew, Jean-Cosme Dodart, Francesco G. Salituro, Albert Jean Robichaud
-
Patent number: 11905309Abstract: 3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.Type: GrantFiled: July 21, 2021Date of Patent: February 20, 2024Assignee: SAGE THERAPEUTICS, INC.Inventors: Gabriel Martinez Botella, Boyd L Harrison, Albert Jean Robichaud, Francesco G. Salituro
-
Patent number: 11851457Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: August 5, 2021Date of Patent: December 26, 2023Assignee: SAGE THERAPEUTICSInventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
-
Patent number: 11613556Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: July 27, 2021Date of Patent: March 28, 2023Assignee: SAGE THERAPEUTICS, INC.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
-
Patent number: 11407782Abstract: Compounds are provided according to Formula (III): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: July 15, 2020Date of Patent: August 9, 2022Assignee: SAGE THERAPEUTICS, INC.Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro
-
Patent number: 11279730Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3 and R6, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: July 30, 2020Date of Patent: March 22, 2022Assignee: SAGE THERAPEUTICS, INC.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin, Daniel La
-
Patent number: 11149054Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: October 18, 2017Date of Patent: October 19, 2021Assignee: SAGE THERAPEUTICS, INC.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
-
Patent number: 11149056Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1b, n, R2A, R2b, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: September 30, 2017Date of Patent: October 19, 2021Assignee: SAGE THERAPEUTICS, INC.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
-
Patent number: 11117924Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, and R3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: July 6, 2016Date of Patent: September 14, 2021Assignee: SAGE THERAPEUTICS, INC.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison
-
Patent number: 11111266Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: October 18, 2017Date of Patent: September 7, 2021Assignee: SAGE THERAPEUTICS, INC.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
-
Patent number: 11104701Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3a, R3b, R4, R5a, R5b, R6a, and R6b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions.Type: GrantFiled: December 20, 2018Date of Patent: August 31, 2021Assignee: SAGE THERAPEUTICS, INC.Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro
-
Patent number: 9512165Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.Type: GrantFiled: April 17, 2014Date of Patent: December 6, 2016Assignee: SAGE THERAPEUTICS, INC.Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
-
Patent number: 9365611Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus.Type: GrantFiled: April 17, 2014Date of Patent: June 14, 2016Assignee: SAGE THERAPEUTICS, INC.Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
-
Publication number: 20160108080Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful NI for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.Type: ApplicationFiled: April 17, 2014Publication date: April 21, 2016Applicant: SAGE THERAPEUTICS, INC.Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
-
Publication number: 20160083417Abstract: Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein, , R1, R2, R3a, R3b, R4a, and R4b are as defined herein, and A is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.Type: ApplicationFiled: April 17, 2014Publication date: March 24, 2016Applicant: SAGE THERAPEUTICS, INC.Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
-
Publication number: 20150291654Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R1, R2, R3, R3?, R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.Type: ApplicationFiled: October 12, 2012Publication date: October 15, 2015Applicant: SAGE THERAPEUTICS, INC.Inventors: Ravindra B. Upasani, Benny C. Askew, Jr., Boyd L. Harrison, Peter Scott DiStefano, Francesco G. Salituro, Albert J. Robichaud
-
Publication number: 20150175651Abstract: Described herein are neuroactive steroids of the Formula (1) or a pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, and/or isotopic variant thereof. Such compounds are envisioned, in certain embodiments, to behave as soft drugs and, in certain embodiments, as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.Type: ApplicationFiled: June 14, 2013Publication date: June 25, 2015Applicant: SAGE THERAPEUTICS, INC.Inventors: Francesco Gerald Salituro, Albert Jean Robichaud
-
Publication number: 20150158903Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.Type: ApplicationFiled: September 7, 2012Publication date: June 11, 2015Applicant: SAGE THERAPEUTICS, INC.Inventors: Ravindra B. Upasani, Boyd L. Harrison, Benny C. Askew, Jr., Jean-Cosme Dodart, Francesco G. Salituro, Albert J. Robichaud
-
Publication number: 20140057885Abstract: Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.Type: ApplicationFiled: August 21, 2013Publication date: February 27, 2014Applicant: SAGE THERAPEUTICS, INC.Inventors: Kiran Reddy, Stephen Jay Kanes